Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Btkis and DRC show a reduction of infections and need of hospitalization towards BR and other chemo-immunotherapies in waldenstrom macroglobulinemia.

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAnna Maria FrustaciVPVeronica PeriDGDiana Giannarelli

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows BTKis reduced infection rates in waldenström macroglobulinemia, indicating a safer treatment option.

Key Points

  • This research aims to evaluate infection complications in patients with waldenström macroglobulinemia treated with BTKis and chemo-immunotherapy.
  • Retrospective multicentre study involving 489 patients across 14 Italian hematology centres.
  • Evaluation of first and second line treatments for infection rates and hospitalization.
  • Analysis of treatments included BTKis, bendamustine-rituximab (BR), and dexamethasone-rituximab-cyclophosphamide (DRC).
  • A total of 111 infections recorded in first-line with a hospitalization rate of 34% for BR and 25% for BTKis.
  • BTKis showed the lowest hospitalization rates and infection rates compared to BR and DRC in both first and second-line.
  • DRC demonstrated a significantly lower infection rate among chemo-immunotherapy regimens, especially for first-line therapy.

Cite This Study

Frustaci et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0a8https://doi.org/10.1182/blood-2025-1833
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune reconstitution with the use of bruton tyrosine kinase inhibitor treatment for patients with Waldenstrom's macroglobulinemia2025
  2. 2Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre2026 · 1 citations
  3. 3Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis2026
  4. 4Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM)2025 · 2 citations
  5. 5Real-world treatment utilization, sequencing patterns, and healthcare resource utilization in Waldenström macroglobulinemia (WM).2026